Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231800 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
- 8
- Study locations
NCT03231800 is a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by Sumitomo Pharma America. The registered enrollment target is 95 participants, below the 141-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (33% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT03231800, a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
- 8
- Study locations
Study Summary
A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG dasotraline
Study Locations (8)
Florida
- Meridien Research - Bradenton
- Meridien Research - Maitland
- Qps-Mra, Llc - South Miami
California
- Avida Inc - Newport Beach
Massachusetts
- South Shore Psychiatric Services PC - Hingham
Nevada
- Center for Psychiatry and Behavioral Medicine, Inc - Las Vegas
Texas
- Bayou City Research, Ltd - Houston
Utah
- Ericksen Reasearch and Development - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03231800
The ClinicalTrials.gov registry entry for NCT03231800 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (33% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03231800 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03231800 about?
NCT03231800 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.". A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
What is the current status of trial NCT03231800?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2017-07-31. Estimated completion is 2019-03-15.
What conditions does trial NCT03231800 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder (ADHD).
What interventions are being tested in trial NCT03231800?
The interventions under investigation include: Placebo (DRUG), dasotraline (DRUG).
Who is sponsoring clinical trial NCT03231800?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03231800 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder (ADHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
COMPLETED · Phase 3
-
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
PRC-063 in an ADULT Workplace Environment
COMPLETED · Phase 3
-
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Improving ADHD Teen Driving - Virtual Reality
RECRUITING · NA
-
Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.